EUCAST susceptibility testing of Manogepix (APX001A) and Six Comparative Agents Against Contemporary Danish Mould Isolates
TIMM 2019
Fosmanogepix (APX001) is Effective in an Immunosuppressed Mouse Model of Fusariosis
TIMM 2019
Fosmanogepix (APX001) is Effective in an Immunosuppressed Mouse Model of Rhizopus oryzae Infection
ID Week 2019
Galactomannan is a Biomarker of Fosmanogepix (APX001) Efficacy in Treating Experimental Invasive Pulmonary Aspergillosis
ID Week 2019
APX001 is Effective Treatment for Murine Coccidioidomycosis
ASM Microbe 2018
Pharmacokinetics/pharmacodynamics (PK/PD) of the novel, first-in-class glycosylphosphatidylinositol (GPI) Inhibitor APX001 in the neutropenic murine invasive candidiasis model against C. albicans (CA), C. glabrata, and C. auris (CAU)
ECCMID 2018
Candida auris is highly in vitro susceptible to APX001A in EUCAST antifungal susceptibility testing
ECCMID 2018
EUCAST susceptibility testing of APX001A: MIC Data for Contemporary Clinical Blood Stream Isolates
TIMM 2017
Isolation of APX001A Resistant Strains and Characterization of Underlying Mechanisms in Candida spp.
ASM 2017
Pharmacodynamics of the active moiety APX001A in human pulmonary and nasal in vitro models of invasive aspergillosis
ECCMID 2017
EUCAST susceptibility testing of APX001A: Impact of choice of microtitre plate type, dilution method and plate storage
ECCMID 2017
In vitro activity of APX001A and comparators against clinical isolates of rare moulds
ECCMID 2017
Efficacy of APX001 in a Murine Model of Cryptococcal Meningitis
ID Week 2017
Efficacy of Oral APX001 in a Murine Model of Cryptococcal Meningitis
ID Week 2017
Fungal Cytological Profiling of Candida albicans Exposed to Diverse Antifungal Agents Including the Novel Gwt1 inhibitor APX001A
ID Week 2017
Evaluation of the In Vitro and In Vivo Antifungal Activity of APX001A/APX001 Against Candida auris
ID Week 2017
APX001 Protects Immunosuppressed Mice from Rhizopus delemar Infection
ID Week 2017
Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001 and to Investigate the Effect of Food on APX001A Bioavailability
ID Week 2017
First-in-Human Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects
ID Week 2017
Absorption, Distribution, and Excretion of [14C]-APX001 after Single-Dose Administration to Rats and Monkeys
ID Week 2017
The Investigational Agent E1210 is Effective for the Treatment of Experimental Invasive Candidiasis Caused by Resistant Candida albicans
ICAAC 2014
In Vitro Activity of E1210 and In Vivo Activity of E1211, a Water-Soluble Prodrug of E1210, in Combination with Other Antifungals
ICAAC 2011
Physicochemical properties and Nonclinical Pharmacokinetics of E1211, a Water-Soluble Prodrug of E1210
ICAAC 2011
In Vitro and In Vivo Antifungal Activities of E1211, a Water-Soluble Prodrug of E1210
ICAAC 2011
In Vitro Activity of a Novel Broad-spectrum Antifungal Agent, E1210, and Comparators Tested against Candida spp.
ICAAC 2011
In Vitro Activity of a Novel Broad-spectrum Antifungal, E1210, Tested against Aspergillus spp. by CLSI and EUCAST Broth Microdilution (BMD) Methods
ICAAC 2011
Pre-clinical Development of Susceptibility Testing Methods for the Novel Antifungal E1210 Tested against Candida: Comparison of CLSI and EUCAST Methods
ICAAC 2011
Preclinical Pharmacokinetics and Toxicology of E1210, a New Broad-Spectrum Antifungal
ICAAC 2010
In Vivo Pharmacodynamic Correlates of Success for E1210 Treatment of Disseminated Candidiasis
ICAAC 2010
Efficacy of Oral E1210, a New Broad-Spectrum Antifungal, in Murine Models of Oropharyngeal Candidiasis, Disseminated Candidiasis, and Pulmonary Aspergillosis
ICAAC 2010
E1210, a New Broad-Spectrum Antifungal, Inhibits Glycosylphosphatidylinositol Biosynthesis in Fungi and Affects Candida albicans Cell Characteristics
ICAAC 2010
* = submitted